Sign in
CompletedPhase 1

An open-label, randomised, single-dose, three-way cross-over trial to assess the pharmacokinetics of NIC24-01 and NIC24-02 oromucosal pouches (a nicotine replacement therapy) in comparison to Nicorette® 4 mg gum in healthy adult smokers under fasted conditions.

Key facts

Who runs it
Niconovum AB
Where
Sweden1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 1
People taking part
15 people enrolled
Started
12 Dec 2024
Ended
30 Jan 2025
Type of study
Interventional
Record updated
21 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
21 November 2024